Today’s $60m deal is focused on Lp(a), a new cardiovascular target for the gene editing company.
Astrazeneca’s $85m Quell collaboration comes after Regeneron’s tie-up with Sonoma and Lilly’s deal with Trex.
Today’s collaboration with Life Edit is a return to the Danish group’s familiar small, early-stage deal strategy.
Lilly is the latest group, after Biogen and Sanofi, to collaborate on Scribe’s novel approach to Crispr editing.
The group’s $270m series A, big for 2023, is not that impressive compared with other years.
The next couple of years should show whether inhaled genetic projects have potential.
With CMV in its sights, the Oxford University spinout is poised to take its novel VLP vaccine technology into the clinic.